TrovaGene, Inc. (TROV)
(Delayed Data from NSDQ)
$3.62 USD
+0.03 (0.84%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.62 USD
+0.03 (0.84%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Trovagene's Onvansertib Shows Response in Phase Ib AML Study
by Zacks Equity Research
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Trovagene (TROV) delivered earnings and revenue surprises of -33.33% and 12.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
TrovaGene Enters Oversold Territor
by Zacks Equity Research
TrovaGene Enters Oversold Territor
TrovaGene (TROV) Enters Oversold Territory
by Zacks Equity Research
TrovaGene, Inc. (TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
TrovaGene, Inc. (TROV) has been struggling lately, but the selling pressure may be coming to an end soon
Trovagene to Focus More on Liquid Biopsy Testing Market
by Zacks Equity Research
Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.
TrovaGene Inks Contract with Boreal Genomics, Stock Down
by Zacks Equity Research
TrovaGene Inc. (TROV), a molecular diagnostic company, recently announced the signing of a long-term Supply and Distribution Agreement with Boreal Genomics.